According to the company, a Phase III clinical study of the compound was being conducted in Japan, the US and Europe. However, following a thorough review of development strategy, Takeda has concluded that TAK-242’s profile does not meet the criteria to support continuation of further development activities. This decision has not been influenced by any concerns over the safety or efficacy of the compound, the company said.
In the US, Takeda recently received the FDA marketing approval for both Kapidex in the treatment of gastroesophageal reflux disease and Uloric in the treatment of chronic management of hyperuricemia in patients with gout.
The company said that it will continue to enhance its established R&D pipeline through a mix of accelerating development projects in all core therapeutic areas, in-house R&D activities, life cycle management, in-licensing and alliances activities.
Takeda is a research-based pharmaceutical company and the product list includes Leuprorelin Acetate, Lansoprazole, Candesartan Cilexetil, and Pioglitazone Hydrochloride. Takeda is building a clinical development network centered in Japan, the United States, Europe and Singapore for speedily delivering pharmaceutical products to the customers.